TIGAR and nasopharyngeal carcinoma: There is growing evidence that high TIGAR expression is closely associated with adverse clinical outcomes of patients with multiple types of cancer including chronic lymphocytic leukemia [9], invasive breast cancer [10], stage II and stage III colorectal cancer [11] and nasopharyngeal carcinoma [12, 13].